GlassScriptPhysician profile
Andrea L Kossler
NPI 1285884106
$91,375.76
in general payments reported to CMS, 2019-2025
20 companies · $7,775 in 2025
The $7,775 reported for 2025 was more than what 89% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
See the full distribution for Ophthalmic Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,772 · 2020: $22K · 2021: $3,101 · 2022: $11K · 2023: $26K · 2024: $19K · 2025: $7,775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $37K · Honoraria: $8,000 · Travel and Lodging: $4,457 · Food and Beverage: $3,080 · Gift: $33.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $37,259.75 |
| Honoraria | $8,000.00 |
| Travel and Lodging | $4,456.52 |
| Food and Beverage | $3,080.37 |
| Gift | $33.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $52,982.74 | 2019-2023 | Tepezza |
| Amgen INC. | $18,735.17 | 2024-2025 | Tepezza |
| Genentech, INC. | $6,037.50 | 2023-2025 | Enspryng, Actemra, Cellcept |
| Argenx US, INC. | $3,112.25 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| H. Lundbeck A S | $2,800.00 | 2023 | Vyepti |
| Abbvie INC. | $2,281.28 | 2024-2025 | |
| Axogen | $1,705.31 | 2019-2025 | Axoguard Nerve Protector, Axoguard Nerve Connector, Avance Nerve Graft |
| Janssen Research & Development, LLC | $1,275.00 | 2024 | |
| Stryker Corporation | $723.87 | 2019-2025 | Na, Medpor Titan, Medpor |
| Mallinckrodt Enterprises LLC | $358.08 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $276.82 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $235.43 | 2023-2025 | |
| Biotissue Holdings INC. | $212.83 | 2025 | |
| Glaukos Corporation | $177.28 | 2025 | Photrexa Viscous and Photrexa |
| Galderma Laboratories, L.P. | $133.32 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kls-Martin L.P. | $105.40 | 2022 | |
| Mallinckrodt Hospital Products INC. | $99.99 | 2023 | Acthar |
| Ani Pharmaceuticals, INC. | $92.80 | 2025 | Purified Cortrophin Gel |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Osteomed LLC | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Kossler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.